XOMAP Key Statistics, Chart & Performance
The current stock price of XOMAP is 26.0501 USD. In the past month the price decreased by -3.05%. In the past year, price increased by 0.39%.
XOMAP Technical Analysis
XOMAP Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to XOMAP. While XOMAP is still in line with the averages on profitability rating, there are concerns on its financial health.
XOMAP Financial Highlights
Over the last trailing twelve months XOMAP reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.96% | ||
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| Debt/Equity | 0.87 |
XOMAP Forecast & Estimates
10 analysts have analysed XOMAP and the average price target is 64.7 USD. This implies a price increase of 148.35% is expected in the next year compared to the current price of 26.0501.
For the next year, analysts expect an EPS growth of 157.93% and a revenue growth 73.62% for XOMAP
XOMAP Ownership
XOMAP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.74 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.62 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XOMAP
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ
What does XOMA ROYALTY CORP - XOMA 8 5/8 PERP do?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Can you provide the latest stock price for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
The current stock price of XOMAP is 26.0501 USD. The price increased by 0.39% in the last trading session.
Does XOMAP stock pay dividends?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a dividend yield of 8.31%. The yearly dividend amount is currently 0.47.
How is the ChartMill rating for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
XOMAP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock traded?
XOMAP stock is listed on the Nasdaq exchange.
What do analysts say about XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
10 analysts have analysed XOMAP and the average price target is 64.7 USD. This implies a price increase of 148.35% is expected in the next year compared to the current price of 26.0501.
What is the expected growth for XOMAP stock?
The Revenue of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is expected to grow by 73.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.